Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024Business Wire • 11h
Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 CountriesBusiness Wire • Wednesday
Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply IssuesBenzinga • 08/12/24
Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday?Benzinga • 08/07/24
Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)Business Wire • 08/07/24
BostonGene Announces Partnership with Takeda to Evaluate Immunotherapies Using AI-Powered Molecular ProfilingBusiness Wire • 08/01/24
Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage PipelineBusiness Wire • 07/31/24
Takeda's AI-Powered Strategy To Optimize Operations And Accelerate Its PipelineSeeking Alpha • 07/19/24
nference Establishes AI Initiative with Takeda to Advance Precision Medicine in Inflammatory Bowel DiseaseBusiness Wire • 07/17/24
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV TherapiesBusiness Wire • 06/24/24
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune ThrombocytopeniaBusiness Wire • 06/23/24
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal CancerBusiness Wire • 06/21/24
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual MeetingBusiness Wire • 06/18/24
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?Benzinga • 06/17/24
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut SyndromeBusiness Wire • 06/17/24
Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)PRNewsWire • 06/14/24